Login
glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review
glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review
glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review
 Next

glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review

Marsoni M251S
Sale price$21.19
Pay 4 payments of $5.30 a month.Shop Pay
Get it in 3 business days with 1 day shipping. Friday, May 29
Florida GLP 1 Insurance Tips: Get Wegovy, Ozempic, Mounjaro or Zepbound Approved Online Florida Surgery & Weight Loss Center Lilly's Zepbound price cut could reshape obesity drug market Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment Encyclopedia MDPI Amazon.com: BIOMA GLP 1 Booster Natural Appetite Control Supplement with Clinically Proven Probiotics, Prebiotics & Postbiotics Support Weight Management & Satiety, (60 Capsules 30 Day Supply) : Health & Household GLP 1 Drug Savings: A Complete Guide for How to Save on Ozempic, Wegovy, and More GoodRx GLP TRIM A Natural GLP 1 Alternative Medi Weightloss
Easy Shipping

Quick Dispatch:

Your glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review orders ship within 1-2 business days.

Delivery Options:

  • Standard: 3-7 business days
  • Fast: 2-3 business days
  • Express: 1-2 business days

Order Tracking:

You'll receive a tracking link by email once your glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review ships.

Need Help?
Questions about glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review, sizing, or delivery? We're just an email away.

Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1 receptor agonists in idiopathic intracranial hypertension The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review in your area.

Get Shipping Estimates

Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy
4.1 ★★★★★
Based on 899 reviews
Sort
Highest Rating
Newest First
Oldest First
Product Reviews
F
Verified Purchase
Filipe Fernandes
Waukegan, US
★★★★★ 5
Great book
Format: Paperback
Love the fact you put examples in python and javascript. Great book.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 10, 2025
E
Verified Purchase
Eddwin Paz
Natrona Heights, US
★★★★★ 5
proper documentation from langchain
Format: Paperback
Liked the book. But Still missing Human in the loop.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 19, 2025
B
Verified Purchase
B. Black
Lake Worth, US
★★★★★ 3
Already outdated
Format: Paperback
Concepts are sound but the code in this book is already obsolete
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on August 5, 2025
J
Joe Faith
Massapequa, US
★★★★★ 5
Unlocking Practical AI: A Developer’s Guide to Building with LLMs and LangChain
Format: Paperback
If you're a developer eager to move beyond LLM experimentation and build robust, context-aware AI applications, this book offers both inspiration and practical guidance. The authors open with a clear passion for the transformative potential of large language models (LLMs) and LangChain, framing these technologies as not just enhancements to the developer’s toolkit, but as gateways to new kinds of “thing-building” superpowers. This sense of possibility is grounded in step-by-step instruction, making the book approachable for those with Python or JavaScript backgrounds who may be new to the world of production-grade AI agents. What stands out is the book’s careful scaffolding: starting with foundational concepts like prompt-based programming and progressing to advanced capabilities such as retrieval-augmented generation, agent planning, and tool integration. Each stage is contextualized with real-world use cases, like customizing chatbots to interact with your own documents, personalizing user experiences through memory, and deploying to production with reliability and security in mind. The focus on chain-of-thought reasoning and LangGraph’s agent architecture demonstrates the authors’ awareness of the current state of AI, where context and planning are just as important as raw language ability.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 17, 2025
T
Tom C Taulli
Pawtucket, US
★★★★★ 5
Excellent Handbook
Format: Paperback
What got my interest in this book is the author. He's well-known as a leader in the LangChain world. And his book did not disappoint. It goes through the whole life cycle of development and there is a lot useful insights. If you are looking to build real-world genAI/agentic apps, then this book is certainly a great choice.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 11, 2025

recommand products

Blue Cross Blue Shield of Massachusetts will stop covering popular GLP-1 weight-loss drugs like Ozempic and Wegovy starting January 1, 2026. The decision comes as the costs for these medications have skyrocketed,
Blue Cross Blue Shield of Massachusetts will stop covering popular GLP-1 weight-loss drugs like Ozempic and Wegovy starting January 1, 2026. The decision comes as the costs for these medications have skyrocketed,
20.15
 Who Gets the Shot? GLP-1 Access by State
Who Gets the Shot? GLP-1 Access by State
26.15
 Excellus clarifies GLP-1 coverage ahead of 2026 formulary changes
Excellus clarifies GLP-1 coverage ahead of 2026 formulary changes
26.69
 Upcoming Insurance Changes for GLP-1 Medications: What You Need to Know
Upcoming Insurance Changes for GLP-1 Medications: What You Need to Know
23.57
 Toujeo (Insulin Glargine Injection for Subcutaneous Use): Side Effects, Uses, Dosage, Interactions, Warnings
Toujeo (Insulin Glargine Injection for Subcutaneous Use): Side Effects, Uses, Dosage, Interactions, Warnings
22.79